Could a common gout drug help people with type 1 diabetes?

NCT ID NCT07247734

Recruiting now Disease control Sponsor: Asger Lund, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether colchicine, a drug used for gout, can improve how the body uses insulin in people with type 1 diabetes who have low-grade inflammation. 26 adults will receive either colchicine or a placebo for four weeks, and their insulin sensitivity will be measured using a clamp procedure. The goal is to see if reducing inflammation can help manage blood sugar better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colchicine
What this could lead to: If it works, this could point toward a new way to improve insulin sensitivity in people with type 1 diabetes, potentially reducing complications.
What could go wrong: This is a small, early-phase trial with only 26 participants. The effect may be small or not clinically meaningful, and colchicine can cause gastrointestinal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC INFLAMMATION INSULIN SENSITIVITY TYPE 1 DIABETES

Contacts and locations

Locations

Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup, Capital Region 2900
RECRUITING

Gentofte Municipality, 2400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.